TRAUMEEL® PRODUCT MONOGRAPH54

Study design Data on children receiving Traumeel® ointment was recorded on standardized

questionnaires by 32 pediatricians. n=157: 87 male, 70 female; median age 10, range 0 12.

Traumeel® was most frequently prescribed for contusions (31.8%), sprains (23.6%), hematomas (16.6%) and dislocations (7.0%). Other uses of Traumeel® included joint effusions, tenosynovitis, fractures, and epicondylitis.

The majority of patients (80%) had symptoms for <1 week before treatment. Traumeel® was applied 1 3 times daily with or without bandaging in 84% of cases. Traumeel® was used as monotherapy in 62%, while 38% received adjuvant

therapies, either pharmaceutical (e.g. analgesics or anti-inflammatories) or non- pharmaceutical (e.g. hot/cold packs or massage).

Duration of treatment: 1 week in two-thirds of patients.

Outcome measures Time when symptoms began to improve. Physician-rated therapy outcome: very good, good, satisfactory, no improvement,

worse.

PEDIATRIC STUDIES

Efficacy of Traumeel® in children with musculoskeletal injury

Ludwig J, Weiser M. Treating pediatric trauma with a homeopathic ointment. J Biomed Ther. 2001; Summer: 8 11.

STUDY DESIGN FORMULATION INDICATION(S) Observational study. Traumeel® ointment. Acute musculoskeletal injury.